Abraxane nab-paclitaxel: Additional Phase III data

Additional data from an open-label, international Phase III trial in 1,052 patients showed that first-line Abraxane plus carboplatin

Read the full 188 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE